ST3GAL4: Potential Drug Targets and Biomarkers (G6484)

Target Name: ST3GAL4

NCBI ID: G6484

ST3GAL4

ST3GAL4: Potential Drug Targets and Biomarkers

ST3GAL4 (SIAT4) is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. Its full name is Spermatostatin-3-Glycoprotein-alpha-L and it is a member of the G protein-coupled receptor (GPCR) family. GPCR is a large family of transmembrane proteins that play a crucial role in cellular signaling, including the regulation of growth, development, and survival.

The ST3GAL4 gene was identified in the late 1990s as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Since then, several studies have demonstrated that ST3GAL4 is involved in a wide range of physiological processes, including cell signaling, angiogenesis, and inflammation.

One of the key functions of ST3GAL4 is its role in cell signaling. GPCRs are involved in the regulation of intracellular signaling pathways, including the production of signaling molecules that transmit information between cells and tissues. ST3GAL4 is part of a family of GPCRs that includes several other proteins, including ST3GAL10, ST3GAL11, and ST3GAL13. These proteins are involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

Another function of ST3GAL4 is its role in angiogenesis. Angiogenesis is the process by which new blood vessels are formed in the body, and it is a critical process for the development and maintenance of tissues. ST3GAL4 is involved in the regulation of angiogenesis, including the formation of blood vessels and the regulation of blood vessel diameter.

In addition to its role in cell signaling and angiogenesis, ST3GAL4 is also involved in the regulation of inflammation. GPCRs have been shown to play a crucial role in the regulation of inflammatory responses, including the regulation of inflammation and the production of pro-inflammatory cytokines. ST3GAL4 is part of a family of GPCRs that includes several other proteins, including ITGA2, ITGB3, and ITGB4. These proteins are involved in the regulation of various cellular processes, including inflammation, immune response, and inflammation regulation.

The potential drug targets for ST3GAL4 are vast and varied. Some studies have suggested that ST3GAL4 may be a potential drug target for various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Others have suggested that ST3GAL4 may be a potential drug target for various cancers, including breast cancer and colorectal cancer.

In addition to its potential drug targets, ST3GAL4 is also a promising biomarker for several diseases. For example, some studies have suggested that ST3GAL4 may be a potential biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Others have suggested that ST3GAL4 may be a potential biomarker for certain cancers, including breast cancer and colorectal cancer.

The study of ST3GAL4 has also identified several potential new therapeutic approaches. For example, several studies have shown that inhibiting the activity of ST3GAL4 may be a potential therapeutic approach for various neurodegenerative diseases. Additionally, several studies have shown that ST3GAL4 is involved in the regulation of angiogenesis, and targeting ST3GAL4 may be a potential therapeutic approach for various diseases, including cancer.

In conclusion, ST3GAL4 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes, including cell signaling, angiogenesis, and inflammation. Its potential drug targets are vast and varied, and it is also a promising biomarker for several diseases. Further research is needed to fully understand the role of ST3GAL4 in

Protein Name: ST3 Beta-galactoside Alpha-2,3-sialyltransferase 4

Functions: A beta-galactoside alpha2-3 sialyltransferase involved in terminal sialylation of glycoproteins and glycolipids (PubMed:8288606, PubMed:8611500). Catalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc- and Galbeta-(1->4)-GlcNAc-terminated glycoconjugates through an alpha2-3 linkage (PubMed:8288606, PubMed:8611500). Plays a major role in hemostasis. Responsible for sialylation of plasma VWF/von Willebrand factor, preventing its recognition by asialoglycoprotein receptors (ASGPR) and subsequent clearance. Regulates ASGPR-mediated clearance of platelets (By similarity). Participates in the biosynthesis of the sialyl Lewis X epitopes, both on O- and N-glycans, which are recognized by SELE/E-selectin, SELP/P-selectin and SELL/L-selectin. Essential for selectin-mediated rolling and adhesion of leukocytes during extravasation (PubMed:25498912). Contributes to adhesion and transendothelial migration of neutrophils likely through terminal sialylation of CXCR2 (By similarity). In glycosphingolipid biosynthesis, sialylates GM1 and GA1 gangliosides to form GD1a and GM1b, respectively (PubMed:8288606). Metabolizes brain c-series ganglioside GT1c forming GQ1c (By similarity). Synthesizes ganglioside LM1 (IV3Neu5Ac-nLc4Cer), a major structural component of peripheral nerve myelin (PubMed:8611500)

The "ST3GAL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST3GAL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets